The clinical focus of Nabila (Nora) N. Bennani, M.D., is on treating lymphomas, while her particular research focus is on T-cell lymphomas. Dr. Bennani's goal is to develop early-phase novel clinical trials with the aim of uncovering novel therapies and improving outcomes for patients. She serves as a principal investigator, co-principal investigator and co-investigator in several ongoing and in-development clinical trials. She is also among select faculty members that provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for relapsed lymphomas.
- Biology and genetic makeup of T-cell lymphomas, including cutaneous T-cell lymphomas, to develop better targeted therapies in various combinations to help improve patient outcomes
- Tumor microenvironment and use of immunotherapy in T-cell lymphomas
- CAR T-cell therapy in patients with relapsed-refractory lymphomas
- How microbiome affects the immune system and outcomes for patients with lymphoma
Significance to patient care
T-cell lymphoma is a rare type of lymphoma with worse outcomes than other lymphoma subtypes. Through the study of biology of T-cell lymphoma, Dr. Bennani's goal is to find effective, chemotherapy-free, novel treatment options that lead to improved outcomes in T-cell lymphoma.
- Editor, Journal of Palliative Care & Medicine, 2010- present
- Chief resident, Oakland University William Beaumont School of Medicine, 2015-2016